López, Néstor
Cuesta, Genoveva
Rodríguez-Vega, Sara
Rosas, Enric
Chumbita, Mariana
Casals-Pascual, Climent
Morata, Laura
Vergara, Andrea
Bodro, Marta
Bosch, Jordi
Herrera, Sabina
Martínez, Jose Antonio
Mensa, Josep
Garcia-Vidal, Carolina
Marcos, María Ángeles
Vila, Jordi
Soriano, Alex
Puerta-Alcalde, Pedro
Funding for this research was provided by:
Instituto de Salud Carlos III (JR20/00012, PI21/00498, ICI21/00103)
Universitat de Barcelona
Article History
Received: 19 June 2023
Accepted: 13 July 2023
First Online: 29 July 2023
Declarations
:
: The authors declare no competing interests.
: CG-V has received honoraria for talks on behalf of Gilead Science, Merck Sharp and Dohme, Pfizer, Jannsen, Novartis, Lilly and a grant support from Gilead Science and Merck Sharp and Dohme. AS has received honoraria for lectures and advisory boards from Pfizer, Merck Sharp and Dohme, Shionogi, Angelini, Menarini, and Gilead Sciences. AS has received grants from Pfizer and Gilead Sciences. P.P.-A. has received honoraria for talks on behalf of Merck Sharp and Dohme, Lilly, ViiV Healthcare and Gilead Science. P.P.-A. has participated in advisory boards for Gilead Science.